Tumor Biology

, Volume 37, Issue 2, pp 2435–2441 | Cite as

Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma

  • Bao-Hong Yuan
  • Wei-Ping Yuan
  • Ru-Hong Li
  • Bang-De Xiang
  • Wen Feng Gong
  • Le-Qun Li
  • Jian-Hong Zhong
Original Article


For patients with advanced hepatocellular carcinoma (HCC), official guidelines recommend palliative treatments such as transarterial chemoembolization (TACE) but not hepatic resection (HR). This study compared short- and long-term outcomes in patients with advanced HCC treated by either HR or TACE. A retrospective analysis was performed for a consecutive series of 444 patients with advanced HCC who underwent HR (n = 339) or TACE (n = 205). Analyses were performed over all participants as well as for propensity score-matched patients to adjust for any baseline differences. When all patients were included in the analysis, the HR and TACE groups showed similar postoperative complication rate and mortality at 30 and 90 days (all P > 0.05). However, median survival time was significantly higher in the HR group (16.4 months) than in the TACE group (11.8 months; P = 0.012). Overall survival at 1, 3, 5, and 7 years was 58, 26, 18, and 18 % in the HR group, higher than the corresponding rates of 49, 14, 12, and 7 % in the TACE group. Similar results were obtained in the analysis of propensity score-matched patients. Therefore, HR can be safe and effective for patients with advanced HCC. Randomized controlled trials are warranted to confirm this finding.


Hepatocellular carcinoma Hepatic resection Overall survival Transarterial chemoembolization 





Hepatocellular carcinoma


Hepatic resection


Overall survival


Portal vein tumor thrombus


Transarterial chemoembolization



The authors thank A. Chapin Rodríguez, PhD, for his language editing, which substantially improved the quality of the manuscript. This work was supported by the National Science and Technology Major Special Project of the Ministry of Science and Technology of China (2012ZX10002010001009), the National Natural Science Foundation of China (81260331, 81160262, 81560460), the Guangxi University of Science and Technology Research Projects (KY2015LX056), the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province (Z2015621, GZZC15-34, Z2014241), and the Innovation Project of Guangxi Graduate Education (YCBZ2015030).


  1. 1.
    Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg. 2013;257(5):929–37.CrossRefPubMedGoogle Scholar
  2. 2.
    Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–55.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.Google Scholar
  5. 5.
    Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Zhong JH, Ke Y, Wang YY, Li LQ. Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension. Gut. 2015;64(3):520–1.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhong JH, Rodriguez AC, Ke Y, Wang YY, Wang L, Li LQ. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore). 2015;94(3), e396.CrossRefGoogle Scholar
  8. 8.
    Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260(2):329–40.CrossRefPubMedGoogle Scholar
  9. 9.
    Zhong JH, Xiang BD, Gong WF, et al. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One. 2013;8(7), e68193.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zhong JH, Li H, Xiao N, et al. Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension. PLoS One. 2014;9(9), e108755.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Zhong JH, You XM, Lu SD, et al. Historical comparison of overall survival after hepatic resection for patients with large and/or multinodular hepatocellular carcinoma. Medicine (Baltimore). 2015;94(35), e1426.CrossRefGoogle Scholar
  12. 12.
    Pesi B, Ferrero A, Grazi GL, et al. Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion: results from a retrospective multicentric study. Am J Surg. 2015;210(1):35–44.CrossRefPubMedGoogle Scholar
  13. 13.
    van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18(6):681–94.CrossRefPubMedGoogle Scholar
  14. 14.
    Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399–424.CrossRefGoogle Scholar
  15. 15.
    D’Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–81.CrossRefPubMedGoogle Scholar
  16. 16.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol. 2015;21(12):3462–71.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37(9):676–91.CrossRefPubMedGoogle Scholar
  19. 19.
    Shaohua L, Qiaoxuan W, Peng S, et al. Surgical strategy for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis. PLoS One. 2015;10(6), e0130021.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS, Lau WY. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2012;118(19):4725–36.CrossRefPubMedGoogle Scholar
  21. 21.
    Ye JZ, Zhang YQ, Ye HH, et al. Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol. 2014;20(45):17141–7.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10(2 Suppl 1):S115–20.CrossRefPubMedGoogle Scholar
  23. 23.
    Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol. 2013;13:60.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18(2):413–20.CrossRefPubMedGoogle Scholar
  25. 25.
    Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011;258(2):627–34.CrossRefPubMedGoogle Scholar
  26. 26.
    Pinter M, Hucke F, Graziadei I, et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012;263(2):590–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012;48(10):1452–65.CrossRefPubMedGoogle Scholar
  28. 28.
    Chen XP, Qiu FZ, Wu ZD, et al. Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol. 2006;13(7):940–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Ban D, Shimada K, Yamamoto Y, et al. Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein. J Gastrointest Surg. 2009;13(11):1921–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Roayaie S, Jibara G, Taouli B, Schwartz M. Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol. 2013;20(12):3754–60.CrossRefPubMedGoogle Scholar
  31. 31.
    Tang QH, Li AJ, Yang GM, et al. Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study. World J Surg. 2013;37(6):1362–70.CrossRefPubMedGoogle Scholar
  32. 32.
    Chen JS, Wang Q, Chen XL, et al. Clinicopathologic characteristics and surgical outcomes of hepatocellular carcinoma with portal vein tumor thrombosis. J Surg Res. 2012;175(2):243–50.CrossRefPubMedGoogle Scholar
  33. 33.
    Lee CR, Lim JH, Kim SH, et al. A comparative analysis of hepatocellular carcinoma after hepatic resection in young versus elderly patients. J Gastrointest Surg. 2012;16(9):1736–43.CrossRefPubMedGoogle Scholar
  34. 34.
    Portolani N, Baiocchi GL, Coniglio A, et al. Limited liver resection: a good indication for the treatment of hepatocellular carcinoma in elderly patients. Jpn J Clin Oncol. 2011;41(12):1358–65.CrossRefPubMedGoogle Scholar
  35. 35.
    Ho MC, Huang GT, Tsang YM, et al. Liver resection improves the survival of patients with multiple hepatocellular carcinomas. Ann Surg Oncol. 2009;16(4):848–55.CrossRefPubMedGoogle Scholar
  36. 36.
    Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134(7):1908–16.CrossRefPubMedGoogle Scholar
  37. 37.
    Aoki T, Kokudo N, Matsuyama Y, et al. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg. 2014;259(3):532–42.CrossRefPubMedGoogle Scholar
  38. 38.
    Chong CC, Lee KF, Ip PC, et al. Pre-operative predictors of post-hepatectomy recurrence of hepatocellular carcinoma: can we predict earlier? Surgeon. 2012;10(5):260–6.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Bao-Hong Yuan
    • 1
  • Wei-Ping Yuan
    • 2
  • Ru-Hong Li
    • 1
  • Bang-De Xiang
    • 2
  • Wen Feng Gong
    • 2
  • Le-Qun Li
    • 2
  • Jian-Hong Zhong
    • 2
  1. 1.Department of General SurgeryYan’An Hospital Affiliated to Kunming Medical UniversityKunmingPeople’s Republic of China
  2. 2.Hepatobiliary Surgery DepartmentAffiliated Tumor Hospital of Guangxi Medical UniversityNanningPeople’s Republic of China

Personalised recommendations